Quantifying Hepatic Mitochondrial Fluxes in Humans
Recruiting
In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/29/2024
Locations: Texas Diabetes Institute - University Health System, San Antonio, Texas +1 locations
Conditions: Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders
Continued Access Study to Evaluate Performance of the Organ Recovery Systems _LifePort® Liver Transporter System, a Machine Perfusion System, for Liver Transplant (PILOT™_CA)
Recruiting
To provide continued access for the LLT system to provide additional safety data in support of the PILOT pivotal efficacy and safety trial
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: Northwestern Memorial Hospital, Chicago, Illinois +3 locations
Conditions: Liver Transplantation
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors
Recruiting
This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in patients with HER2-positive advanced solid tumors with or without brain metastases. The study will consist of three phases: Phase 1a (dose escalation with ZN-A-1041 monotherapy), Phase 1b (dose escalation with ZN-A-1041 combination therapy) and Phase 1c (dose expansion with ZN-A-1041 combination therapy).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: ACRC/Arizona Clinical Research Center, Inc, Tucson, Arizona +22 locations
Conditions: Advanced Solid Tumors, HER2-positive Breast Cancer
Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients
Recruiting
This study will evaluate the efficacy of losartan (LOS), an FDA-approved transforming growth factor beta-1 (TGF-β1) blocker, to decrease radiation induced fibrosis (RIF) in the breast and the lung of breast cancer patients, testing the hypothesis that Losartan will decrease RIF, TGF- β1 and cellular senescence/inflammation in the breast and the lung of irradiated breast cancer patients relative to placebo treatment and consequently improve clinical outcomes in breast cancer patients.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: Vail Health Shaw Cancer Center, Edwards, Colorado
Conditions: Radiation Induced Fibrosis
Diet and Cognitive Training in Hematologic Cancer Survivors
Recruiting
The goal of this clinical trial is to examine feasibility of a cognitive intervention program in blood cancer survivors. The main questions it aims to answer are: * is it feasible to combine a ketogenic diet supplementation and online cognitive training in an intervention program * will patients using the combined intervention program have improved cognitive functioning compared to those who don't use it * how long will the intervention programs effects last Participants randomized to the inte... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
08/29/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cognitive Impairment, Hematologic Malignancy
ENCALM: a Study of ENX-102 As a Monotherapy Treatment in Patients with Generalized Anxiety Disorder
Recruiting
The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/29/2024
Locations: IMA Clinical Research Phoenix, Phoenix, Arizona +31 locations
Conditions: Generalized Anxiety Disorder
TRUDI: TDXD+Durva in HER2+/low IBC
Recruiting
The purpose of this study is to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn whether the intervention works in treating Human Epidermal growth factor Receptor-2 (HER2)-expressing inflammatory breast cancer. The names of the study drugs involved in this study are: * Trastuzumab deruxtecan * Durvalumab
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +2 locations
Conditions: Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer, HER2 Low Breast Adenocarcinoma, Breast Cancer
Exercise Neuroprotection in Parkinson's Disease
Recruiting
The purpose of this study is to explore the relationships of exercise on inflammation in the body of older adults and people with Parkinson's disease (PD). This is important research for older adults but is especially important for people with PD because neuroinflammation is the main pathological mechanism that is responsible for neuron cell death in this neurodegenerative disease. As PD is a progressive disease, halting or slowing the degeneration is an important research target. Halting or slo... Read More
Gender:
ALL
Ages:
Between 30 years and 85 years
Trial Updated:
08/29/2024
Locations: Gait and Balance Laboratory, 217 Bigelow Health Sciences Building, UNLV, Las Vegas, Nevada
Conditions: Parkinson Disease
Patient Experience and Quality of Patch Testing on the Legs vs Back
Recruiting
The gold standard for the diagnosis of allergic contact dermatitis is patch testing, during which allergens are affixed to the skin underneath tape and left for multiple days. A large area of clear skin is thus required for successful testing. While the back is traditionally thought to be the ideal area for testing, the thighs may be more available or advantageous. This study seeks to randomize patients undergoing patch testing to have patches placed on the back or the thighs. The investigators... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
08/29/2024
Locations: Park Nicollet Contact Dermatitis Clinic, Minneapolis, Minnesota
Conditions: Allergic Contact Dermatitis
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
Recruiting
This study will evaluate the safety and activity of AB-101 in combination with rituximab in B-cell associated autoimmune diseases where rituximab is currently FDA approved (e.g., Rheumatoid Arthritis (RA), Pemphigus Vulgaris (PV), Granulomatosis with polyangiitis (GPA)/microscopic polyangiitis (MPA) as a therapeutic, or is recommended (e.g., in Systemic Lupus Erythematosus (SLE) as a cornerstone for disease management.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: IRIS Research and Development, LLC, Plantation, Florida
Conditions: Rheumatoid Arthritis, Pemphigus Vulgaris, Granulomatosis With Polyangiitis, Systemic Lupus Erythematosus
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Recruiting
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conducted in two major parts which are further organized into two sub-parts. Part A Dose Escalation is a modified 3+3 with the first two cohorts consisting of one subject each based on the low clinical start... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: University of Southern California, Los Angeles, California +7 locations
Conditions: Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma, Gastrointestinal Cancer, Lung Cancer, Prostate Cancer, Breast Cancer
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
Recruiting
RATIONALE: Studying samples of sputum and tissue in the laboratory from patients with dysplasia or cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This laboratory study is looking at biomarkers in patients with respiratory tract dysplasia or lung cancer, head and neck cancer, or aerodigestive tract cancer.
Gender:
ALL
Ages:
Between 21 years and 90 years
Trial Updated:
08/28/2024
Locations: University of Colorado Cancer Center at UC Health Sciences Center, Aurora, Colorado
Conditions: Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Precancerous Condition